Glenmark Pharmaceuticals Ltd.

₹1959.2

Glenmark Pharmaceuticals Ltd.

Add Alert
Add Watchlist

₹1959.2

₹1959.2

6.5 (0.33%) - 2 Oct 2025 04:26 PM

About Company

Glenmark Pharmaceuticals Limited is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark’s formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.

Market Cap. ₹ 55,289 Cr.
52 Week - High/Low ₹ 2,285/1,276
P/E Ratio 37.18
P/B Ratio 2.26
Enterprise Value ₹ 60,176 Cr.
ROE % 6.78
RSI Value 40.98
EMA 50 1984.48
EMA 200 1721.9
Market Cap. ₹ 55,289 Cr.
52 Week - High/Low ₹ 2,285/1,276
P/E Ratio 73.38
P/B Ratio 6.25
Enterprise Value ₹ 53,693 Cr.
ROE % 12.56
RSI Value 40.98
EMA 50 1984.48
EMA 200 1721.9

Valuation

Calculators

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages

Insight market
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED | All logos and Trademarks registered with their respective owners.